论文部分内容阅读
目的通过检测血清胃蛋白酶原Ⅰ(pepsinogen I,PGI)、Ⅱ(PGII)的含量,探讨胃溃疡及胃癌患者治疗前后血清PGI、PGII及PGI/PGII的变化规律。方法收集2005年5月至2007年5月在我院消化内镜中心行胃镜检查确诊为消化性溃疡患者48例,胃癌33例(其中复发病例13例),并设正常对照组,采用免疫比浊法(immunoturbidimetric assay)测定治疗前后患者血清PGI及PGII含量,并计算PGI/PGII即PGR。结果消化性溃疡患者血清PGI及PGII分别为(180.15±41.12)mg/L及(23.76±7.57)mg/L,较对照组明显升高(P﹤0.05),而在治愈后与正常组比较无显著性差异。胃癌患者血清PGI及PGR分别为(94.05±40.74)mg/L、5.97±3.33,较对照组明显降低(P﹤0.05),术后较术前降低更为明显。复发者PGI及PGII分别为(97.65±37.44)mg/L和(16.10±5.72)mg/L,较术后明显升高(P﹤0.05)。结论测定血清PGI、PGII及PGR值对胃溃疡及胃癌患者疗效的判定及复发诊断具有重要的参考意义。
Objective To investigate the changes of serum PGI, PGII and PGI / PGII in patients with gastric ulcer and gastric cancer before and after treatment by detecting the content of pepsinogen Ⅰ (PGI) and Ⅱ (PGII). Methods From May 2005 to May 2007, 48 cases of peptic ulcer patients diagnosed as peptic ulcer and 33 cases of gastric cancer (including 13 recurrent cases) were enrolled in the digestive endoscopy center of our hospital. A normal control group was also enrolled. Immunoturbidimetric assay was used to determine serum PGI and PGII levels before and after treatment and PGI / PGII, PGR, was calculated. Results The serum PGI and PGII in patients with peptic ulcer were (180.15 ± 41.12) mg / L and (23.76 ± 7.57) mg / L respectively, which were significantly higher than those in control group (P <0.05) Significant difference. The serum PGI and PGR in patients with gastric cancer were (94.05 ± 40.74) mg / L and 5.97 ± 3.33, respectively, which were significantly lower than those in the control group (P <0.05). PGI and PGII in recurrence patients were (97.65 ± 37.44) mg / L and (16.10 ± 5.72) mg / L, respectively, which were significantly higher than those in patients with recurrence (P <0.05). Conclusion The determination of serum PGI, PGII and PGR values in gastric ulcer and gastric cancer patients with the determination of efficacy and recurrence diagnosis has important reference value.